Statin as a therapeutic agent in gastroenterological cancer |
| |
Authors: | Norio Uemura Hiromitsu Hayashi Hideo Baba |
| |
Institution: | Norio Uemura, Hiromitsu Hayashi, Hideo Baba, Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan |
| |
Abstract: | Statins inhibit 3-hydroxy-3-methylglutaryl-CoA reductase, the rate-limiting enzyme of the mevalonate pathway, and are widely used as an effective and safe approach handle hypercholesterolemia. The mevalonate pathway is a vital metabolic pathway that uses acetyl-CoA to generate isoprenoids and sterols that are crucial to tumor growth and progression. Multiple studies have indicated that statins improve patient prognosis in various carcinomas. Basic research on the mechanisms underlying the antitumor effects of statins is underway. The development of new anti-cancer drugs is progressing, but increasing medical costs from drug development have become a major obstacle. Readily available, inexpensive and well-tolerated drugs like statins have not yet been successfully repurposed for cancer treatment. Identifying the cancer patients that may benefit from statins is key to improved patient treatment. This review summarizes recent advances in statin research in cancer and suggests important considerations for the clinical use of statins to improve outcomes for cancer patients. |
| |
Keywords: | Statin HMG CoA reductase inhibitor Mevalonate pathway Cancer |
|
| 点击此处可从《World journal of gastrointestinal oncology》浏览原始摘要信息 |
|